Dr. Mark Boguniewicz, MD
Allergy & Immunology (Allergy Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Colorado since 1990, according to the Colorado Department of Regulatory Agencies. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy Physician primary
CO license 30168 (first issued 1990; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 12 companies reported 59 payments worth $41,971 in total to this clinician.
| Incyte Corporation | $19,611 |
|---|---|
| Eli Lilly and Company | $9,139 |
| Arcutis Biotherapeutics, Inc. | $4,366 |
| Pfizer Inc. | $4,050 |
| Amgen Inc. | $2,250 |
| Organon LLC | $1,678 |
| AstraZeneca Pharmaceuticals LP | $212 |
| Leo Pharma Inc. | $208 |
| Consulting Fee | $36,386 |
|---|---|
| Travel and Lodging | $3,828 |
| Food and Beverage | $1,758 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Jan 2, 2025 | Consulting Fee | $6,936 |
| Eli Lilly and Company Mar 11, 2025 | Consulting Fee EBGLYSS · Immunology | $4,900 |
| Incyte Corporation Jun 24, 2025 | Consulting Fee OPZELURA · Dermatology | $3,810 |
| Incyte Corporation Dec 9, 2025 | Consulting Fee OPZELURA · Dermatology | $3,810 |
| Arcutis Biotherapeutics, Inc. Feb 20, 2025 | Consulting Fee Zoryve · Dermatology | $3,000 |
| Pfizer Inc. Dec 22, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $2,700 |
| Incyte Corporation Jun 24, 2025 | Consulting Fee OPZELURA · Dermatology | $2,540 |
| Eli Lilly and Company Mar 11, 2025 | Consulting Fee EBGLYSS · Immunology | $2,450 |
| Amgen Inc. Oct 28, 2025 | Consulting Fee | $2,250 |
| Pfizer Inc. Dec 22, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $1,350 |
All 33 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Pfizer Inc. Dec 22, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $2,700 |
| Pfizer Inc. Dec 22, 2025 | Consulting Fee CIBINQO · Inflammation & Immunology | $1,350 |
| Incyte Corporation Dec 9, 2025 | Consulting Fee OPZELURA · Dermatology | $3,810 |
| Organon LLC Nov 28, 2025 | Travel and Lodging VTAMA · Dermatology · travel to Jersey City, NJ · in-kind | $96.10 |
| Organon LLC Nov 28, 2025 | Travel and Lodging VTAMA · Dermatology · travel to Jersey City, NJ · in-kind | $70.00 |
| Arcutis Biotherapeutics, Inc. Nov 18, 2025 | Consulting Fee Zoryve · Dermatology | $1,304 |
| Incyte Corporation Nov 4, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Orlando, FL | $365 |
| Incyte Corporation Nov 4, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Denver, CO | $35.00 |
| Amgen Inc. Oct 28, 2025 | Consulting Fee | $2,250 |
| Organon LLC Oct 9, 2025 | Travel and Lodging VTAMA · Dermatology · travel to Jersey City, NJ · in-kind | $642 |
| Organon LLC Oct 9, 2025 | Travel and Lodging VTAMA · Dermatology · travel to Jersey City, NJ · in-kind | $384 |
| Organon LLC Oct 9, 2025 | Travel and Lodging VTAMA · Dermatology · travel to Jersey City, NJ · in-kind | $167 |
| Incyte Corporation Aug 13, 2025 | Consulting Fee OPZELURA · Dermatology | $635 |
| Incyte Corporation Jun 24, 2025 | Consulting Fee OPZELURA · Dermatology | $3,810 |
| Incyte Corporation Jun 24, 2025 | Consulting Fee OPZELURA · Dermatology | $2,540 |
| Incyte Corporation May 29, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Palm Beach, FL | $73.93 |
| Incyte Corporation May 29, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Denver, CO | $70.00 |
| Incyte Corporation May 29, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Palm Beach, FL | $6.97 |
| Incyte Corporation May 28, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Palm Beach, FL | $495 |
| Incyte Corporation May 28, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Palm Beach, FL | $406 |
| Incyte Corporation May 28, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Palm Beach, FL | $77.94 |
| Incyte Corporation May 28, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Denver, CO | $70.00 |
| Incyte Corporation May 28, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Denver, CO | $26.10 |
| Eli Lilly and Company Mar 31, 2025 | Travel and Lodging EBGLYSS · Immunology · travel to SAN DIEGO, CA | $250 |
| Eli Lilly and Company Mar 24, 2025 | Consulting Fee | $700 |
| Eli Lilly and Company Mar 11, 2025 | Consulting Fee EBGLYSS · Immunology | $4,900 |
| Eli Lilly and Company Mar 11, 2025 | Consulting Fee EBGLYSS · Immunology | $2,450 |
| Eli Lilly and Company Feb 27, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $165 |
| Eli Lilly and Company Feb 27, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $165 |
| Eli Lilly and Company Feb 27, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $132 |
| Eli Lilly and Company Feb 27, 2025 | Travel and Lodging travel to SAN DIEGO, CA · in-kind | $132 |
| Arcutis Biotherapeutics, Inc. Feb 20, 2025 | Consulting Fee Zoryve · Dermatology | $3,000 |
| Incyte Corporation Jan 2, 2025 | Consulting Fee | $6,936 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $2,336 in research payments for these studies, mostly to the institutions running them.
- TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
Incyte Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.